COVID-19 vaccination in Hungary

Last updated

COVID-19 vaccination in Hungary
Date27 December 2020 (2020-12-27) – present
Location Hungary
Cause COVID-19 pandemic in Hungary

COVID-19 vaccination in Hungary is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

Contents

Vaccination program

Background

Reports in March 2021 stated that Hungary was the first country in the EU to "begin using China’s Sinopharm BIBP and Russia’s Sputnik V vaccines, even as polling showed that public trust in non-EU approved vaccines was low". [1] The European Commission's Vaccine Passport plan excluded the Sputnik and Sinopharm products because they were not "EU authorized vaccines". One suggestion to resolve that issue was that "Russian and Chinese vaccine producers submit their products to the EMA for testing and authorization". [2] At the end of March 2021, Hungary also granted emergency use licenses to two more vaccines, CanSino (from China) and Covishield (the AstraZeneca vaccine produced by the Serum Institute of India). [3]

Vaccines on order

VaccineApprovalDeployment
Oxford–AstraZeneca Green check.svg YesGreen check.svg Yes
Sinopharm BIBP Green check.svg YesGreen check.svg Yes
Pfizer–BioNTech Green check.svg YesGreen check.svg Yes
Moderna Green check.svg YesGreen check.svg Yes
Janssen Green check.svg YesGreen check.svg Yes
Sputnik V Green check.svg YesGreen check.svg Yes
Convidecia Green check.svg YesDark Red x.svg No
Novavax Green check.svg YesDark Red x.svg No
Sanofi–GSK PendingDark Red x.svg No
CureVac PendingDark Red x.svg No
Valneva PendingDark Red x.svg No

Government response

On 17 March, the Surgeon General announced that the National Safety Laboratory of National Health Security Center had successfully isolated COVID-19 from a Hungarian patient's sample, which it could use for the research and development of a new Hungarian vaccine. [4] [5] A consortium founded by the Department of Immunology at the Faculty of Sciences of Eötvös Loránd University, the Institute of Biology at the Science Faculty of the University of Pécs, Richter Gedeon and ImmunoGenes is involved in international biotechnological developments. [6] [7] Imre Kacskovics, leader of Immunology Department of ELTE, said the product currently in the first phase of development won't be a vaccine, but provide passive immunity. It will not prepare the body to fight against the virus. [8] Some days after the successful isolation, the Bioinformatic Research Team of Szentágothay János Research Center at the University of Pécs and the university's virologists made the genome of the new SARS-CoV-2 human coronavirus available in Hungary. [9] [10]

Related Research Articles

Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.

Sinopharm (company) Chinese state-owned enterprise

China National Pharmaceutical Group Corporation (CNPGC), commonly referred to as Sinopharm, is a Chinese state-owned enterprise. The corporation was the indirect major shareholder of publicly traded companies Sinopharm Group, China Traditional Chinese Medicine, Shanghai Shyndec Pharmaceutical, and Beijing Tiantan Biological Products.

COVID-19 pandemic in Hungary Ongoing COVID-19 viral pandemic in Hungary

The COVID-19 pandemic in Hungary is part of the ongoing worldwide pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2. On 4 March 2020, the first cases in Hungary were announced. The first coronavirus-related death was announced on 15 March on the government's official website.

COVID-19 vaccine Vaccine designed to provide acquired immunity against SARS-CoV-2

A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 (COVID‑19).

Cecília Müller Hungarian physician and Chief Medical Officer of Hungary

Cecília Györgyi Müller is a Hungarian physician and Chief Medical Officer of Hungary. She is the head of NNK and has also served as a member of the government's Coronavirus Taskforce.

BioNTech German biotechnology company

BioNTech SE is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer.

Sputnik V COVID-19 vaccine Vaccine against COVID-19

Sputnik V or Gam-COVID-Vac is an adenovirus viral vector vaccine for COVID-19 developed by the Gamaleya Research Institute of Epidemiology and Microbiology in Russia. It is the world's first registered combination vector vaccine for the prevention of COVID-19, having been registered on 11 August 2020 by the Russian Ministry of Health.

Vaccine diplomacy Use of vaccines

Vaccine diplomacy, a form of medical diplomacy, is the use of vaccines to improve a country's diplomatic relationship and influence of other countries. Meanwhile, vaccine diplomacy also "means a set of diplomatic measures taken to ensure access to the best practices in the development of potential vaccines, to enhance bilateral and/or multilateral cooperation between countries in conducting joint R&D, and, in the case of the announcement of production, to ensure the signing of a contract for the purchase of the vaccine at the shortest term." Although primary discussed in the context of the supply of COVID-19 vaccines, it also played a part in the distribution of the smallpox vaccine.

Sinopharm BIBP COVID-19 vaccine Vaccine against COVID-19

The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV, the Sinopharm COVID-19 vaccine, or BIBP vaccine, is one of two inactivated virus COVID-19 vaccines developed by Sinopharm's Beijing Institute of Biological Products. It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants. BBIBP-CorV shares similar technology with CoronaVac and Covaxin, other inactivated virus vaccines for COVID-19. Its product name is SARS-CoV-2 Vaccine, not to be confused with the similar product name of CoronaVac.

The COVID-19 vaccination program in the Philippines is an ongoing mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

The COVID-19 vaccination in Morocco is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

Various kinds of software have been developed and used for mitigating the COVID-19 pandemic. These include mobile apps for contact tracing and notifications about infection risks, digital passports verifying one's vaccination status, software for enabling – or improving the effectiveness of – lockdowns and social distancing in general, Web software for the creation of related information services, and software for the research and development for COVID-19 mitigation.

COVID-19 vaccination in Bangladesh Immunisation programme against COVID-19 in Bangladesh

Bangladesh began the administration of COVID-19 vaccines on 27 January 2021 while mass vaccination started on 7 February 2021.

Sputnik Light Vaccine against COVID-19

Sputnik Light is a single dose COVID-19 vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology. It consists of the first dose of the Sputnik V vaccine, which is based on the Ad26 vector, and it can be stored at a normal refrigerator temperature of 2–8 °C (36–46 °F). The institute says this version would be ideally suited for areas with acute outbreaks, allowing more people to be vaccinated quickly. It will also be used as a third (booster) dose for those who received Sputnik V at least 6 months earlier.

COVID-19 vaccination in Sri Lanka Plan to immunize against COVID-19

COVID-19 vaccination in Sri Lanka is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, in response to the ongoing pandemic in the country. As of late July, the Sinopharm BIBP vaccine accounted for 78% of the total 13.8 million vaccines obtained by Sri Lanka to date. The United States donated over 1.5 million Moderna vaccine through COVAX.

COVID-19 vaccination in Comoros is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

The COVID-19 vaccination in the United Arab Emirates is an ongoing mass immunization campaign, in response to the ongoing pandemic.

COVID-19 vaccine clinical research

COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness and safety. Thirty vaccines are authorized for use by national governments, including eight approved for emergency or full use by at least one WHO-recognised stringent regulatory authority; while five are in Phase IV. 204 vaccines are undergoing clinical trials that have yet to be authorized. Nine clinical trials consider heterologous vaccination courses.

Vaccine passports during the COVID-19 pandemic Use of immunity passports for COVID-19 vaccination

A vaccine passport or proof of vaccination is an immunity passport employed as a credential in countries and jurisdictions as part of efforts to control the COVID-19 pandemic via vaccination. A vaccine passport is typically issued by a government or health authority, and usually consists of a digital or printed record. Some credentials may include a scannable QR code, which can also be provisioned via mobile app. It may or may not use a COVID-19 vaccine card as a basis of authentication.

References

  1. Spike, Justin (12 March 2020). "Hungary emerges as an EU vaccination star amid surging cases". Associated Press . Retrieved 31 July 2021.
  2. Vaski, Tamás (18 March 2021). "EC Vaccine Passport Proposal Excludes Sputnik and Sinopharm". Hungary Today . Retrieved 31 July 2021.
  3. "CMO: Hungary's medicines authority grants licences for two more vaccines". About Hungary. 23 March 2021. Retrieved 6 August 2021.
  4. "Magyarok izolálták a koronavírust – mit jelent ez?" [Hungarians isolate coronavirus what happens next?]. 24.hu (in Hungarian). 17 March 2020. Retrieved 18 March 2020.
  5. "Országos tisztifőorvos: sikeresen izolálták az NNK laborjában a koronavírust" [National Chief Medical Officer: coronavirus successfully isolated in NNK laboratory]. Koronavírus.gov.hu (in Hungarian). 17 March 2020. Retrieved 17 March 2020.
  6. "Koronavírus – Magyar gyógyszerfejlesztés kezdődik" [Hungarian coronavirus drug development begins] (in Hungarian). Népszava. 14 March 2020. Retrieved 18 March 2020.
  7. "Exkluzív részleteket tudtunk meg a koronavírus elleni magyarországi gyógyszer fejlesztéséről" [Exclusive: details of the first Hungarian coronavirus drug]. portfolio.hu (in Hungarian). 17 March 2020. Retrieved 18 March 2020.
  8. "Magyar gyógyszert fejlesztenek a koronavírus ellen" [Developing the Hungarian coronavirus drug] (in Hungarian). Index.hu. 17 March 2020. Retrieved 1 August 2021.
  9. "Megvan az első magyar koronavírus genom" [I have the first Hungarian coronavirus genome]. index.hu (in Hungarian). 21 March 2020. Retrieved 21 March 2020.
  10. "Virológia Pécs". facebook.com (in Hungarian). Retrieved 21 March 2020.